Coronary versus Intravenous abCiximab administration during Emergency Reperfusion Of ST-segment elevation myocardial infarction – the CICERO trial - CICERO

niversity Medical Center of Groningen0 个研究点开始时间: 2008年7月16日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- a diagnosis of STEMI defined by
•a. chest pain suggestive for myocardial ischemia for at least 30 minutes before hospital admission
•b. time from onset of symptoms of less than 12 hours
•c. ECG with ST-segment deviation of more than 0.1 mV in 2 or more leads
•- primary PCI performed
•- verbal followed by written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- rescue PCI after thrombolytic therapy
•- need for emergency coronary artery bypass grafting
•- presence of cardiogenic shock
•- known existence of a life-threatening disease with a life expectancy of less than 6 months
•- inability to provide informed consent
•- age below 18 years
•- contra-indications for the use of abciximab (active internal bleeding, history of stroke within 2 years, recent major surgery or intracranial or intraspinal trauma or surgery within 2 months, intracranial neoplasm, arteriovenous malformation or aneurysm, bleeding diathesis, severe uncontrolled hypertension, thrombocytopenia, vasculitis, hypertensie or diabetic retinopathy, severe liver or kidney failure, and hypersensitivity to murine proteins).

发起方

niversity Medical Center of Groningen